September 14, 2017 05:59 AM EDT
R&D

GSK lines up a shot at a block­buster mar­ket as new CEO pre­pares to tack­le Mer­ck ri­val head on

John Carroll

Editor & Founder

New Glax­o­SmithK­line CEO Em­ma Walm­s­ley is one big step clos­er to tak­ing a shot at a block­buster mar­ket­ing pro­gram to­day af­ter an FDA pan­el re­view …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

GSK kicks off Blenrep re­launch plans with clear­ance from UK reg­u­la­tors

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

Unit­ed­Health re­ports 'unusu­al and un­ac­cept­able' earn­ings as Medicare costs climb

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times